PeptideJournal
Guides22 min read

Best Peptides for Women Over 40

Your body after 40 is running on different rules than it did at 30. Sleep that used to come easily now fragments. Weight collects around your midsection despite the same habits. Joints ache. Skin thins. Brain fog rolls in without warning. Recovery from a hard workout takes days instead of hours.

Your body after 40 is running on different rules than it did at 30. Sleep that used to come easily now fragments. Weight collects around your midsection despite the same habits. Joints ache. Skin thins. Brain fog rolls in without warning. Recovery from a hard workout takes days instead of hours.

Most of this traces back to one thing: shifting hormones. Estrogen and progesterone begin their unpredictable decline during perimenopause, which can start as early as the late 30s and typically lasts 4 to 10 years before menopause. Growth hormone drops steadily. And the downstream effects ripple through nearly every system in your body.

Here's what the research says about peptides that may help -- what works, what's still being studied, and what you should know before considering any of it.

Table of Contents

What Happens to Your Body After 40

The hormonal changes women experience after 40 aren't gradual like turning down a dimmer switch. They're more like a series of unpredictable power surges followed by brownouts.

Estrogen fluctuates, then drops. During perimenopause, estrogen levels can swing wildly -- sometimes higher than your 20s, sometimes crashing to postmenopausal levels -- before eventually settling into permanent decline. This hormonal instability drives hot flashes, sleep disruption, mood changes, and the stubborn weight gain that so many women describe.

Collagen disappears fast. Women lose approximately 30% of their skin collagen in the first five years after menopause, with an ongoing decline of about 2% per year thereafter [1]. Skin thickness decreases by 1.13% per postmenopausal year [2]. This collagen loss parallels bone density decline -- both are driven by falling estrogen, not just aging itself.

Growth hormone declines. Like men, women experience significant GH reduction with age, affecting body composition, sleep quality, recovery, and tissue repair. However, the interaction between estrogen and the GH/IGF-1 axis creates unique considerations -- oral estrogen therapy can actually blunt IGF-1 production, complicating how GH peptides work in women on HRT [3].

Muscle mass drops, fat mass rises. Sarcopenia -- age-related muscle loss -- accelerates after menopause. At the same time, fat preferentially accumulates around the midsection, shifting from a gynoid (hips and thighs) to an android (abdominal) distribution pattern.

Bone weakens. Women can lose up to 20% of their bone density in the 5-7 years following menopause, driven primarily by estrogen loss [4].

Brain fog is real. Declining estrogen affects neurotransmitter systems, mitochondrial function in brain cells, and neuroinflammation. The cognitive changes many women report during perimenopause aren't imagined -- they're measurable.

Peptides can't replace what estrogen does. But they can support several of the systems that falter as hormones shift, often through different pathways than traditional hormone replacement therapy.

Best Peptides for Hormonal Balance and Menopause Symptoms

These peptides work on the hormonal axis itself, influencing how your body produces and regulates reproductive hormones.

Gonadorelin

Gonadorelin is synthetic GnRH -- the hormone your hypothalamus releases to signal your pituitary gland to produce LH and FSH, which in turn stimulate estrogen and progesterone production from the ovaries.

During perimenopause, the signaling between hypothalamus, pituitary, and ovaries becomes erratic. Gonadorelin, when administered in a pulsatile fashion that mimics the body's natural rhythm, can help regulate this communication. It has been used clinically for treating amenorrhea, infertility caused by hypothalamic dysfunction, and menstrual irregularity [5].

An important distinction: continuous gonadorelin exposure actually suppresses ovarian function (this is how GnRH agonists like goserelin work in breast cancer treatment). The therapeutic benefit for perimenopausal women comes from pulsatile, physiologic dosing -- not continuous administration. This requires careful clinical management.

For perimenopausal women with irregular cycles and fluctuating hormones, gonadorelin represents a way to support the body's own hormonal regulation rather than supplying hormones externally. However, once a woman is truly postmenopausal and the ovaries have stopped responding, gonadorelin is no longer effective for estrogen production.

Kisspeptin

Kisspeptin sits upstream of GnRH in the reproductive hormone cascade. It's the peptide that tells your hypothalamus when and how much GnRH to release. Research shows kisspeptin integrates metabolic signals with reproductive function -- meaning your body's energy status directly affects your hormonal output through this pathway [6].

For women in perimenopause, kisspeptin is interesting because it may help modulate the erratic GnRH pulsatility that drives many menopausal symptoms. However, most kisspeptin research in humans has focused on men and on fertility applications in younger women. Its specific effects on perimenopausal symptom relief are still being studied.

Best Peptides for Body Composition and Fat Loss

The metabolic shift after 40 is one of the most frustrating changes women face. These peptides address fat loss and body composition through different mechanisms.

Semaglutide

Semaglutide is a GLP-1 receptor agonist that has become one of the most effective pharmacological tools for weight management. The STEP 1 trial showed average body weight reduction of 14.9% over 68 weeks [7]. The four-year SELECT trial data showed sustained weight loss of 10.2% and a 20% reduction in major cardiovascular events [8].

Women in the trials actually lost slightly more weight than men (-11.1% vs. -7.5% treatment difference from placebo) [8]. For women over 40 dealing with the metabolic resistance that comes with hormonal changes, semaglutide addresses multiple pathways: appetite regulation, insulin sensitivity, and slowed gastric emptying.

It's FDA-approved for weight management as Wegovy and for type 2 diabetes as Ozempic. Read more in our guide to Best Peptides for Fat Loss.

Tirzepatide

Tirzepatide is a dual GIP/GLP-1 receptor agonist that has shown even greater weight loss in clinical trials -- averaging 20% or more. The dual mechanism may offer advantages for women dealing with insulin resistance, which becomes increasingly common after 40 and especially after menopause, when estrogen's insulin-sensitizing effects diminish.

Tirzepatide is FDA-approved as Mounjaro for type 2 diabetes and Zepbound for weight management.

Tesamorelin

Tesamorelin is an FDA-approved GHRH analog that stimulates your pituitary gland to release growth hormone in a natural pulsatile pattern. Pooled Phase 3 trials showed it reduces visceral adipose tissue by approximately 15.4% with additional improvements in triglycerides and cholesterol ratios [9].

Visceral fat -- the deep abdominal fat surrounding your organs -- is the metabolically dangerous type. It increases after menopause as body fat redistribution shifts toward the midsection. Tesamorelin specifically targets this visceral compartment without affecting subcutaneous fat or limb fat.

For women over 40, one important consideration: tesamorelin raises IGF-1 levels, and the relationship between IGF-1 and breast cancer risk is well-documented in the literature. Any woman considering tesamorelin should discuss this with her physician, particularly those with personal or family history of hormone-sensitive cancers.

AOD-9604

AOD-9604 is a modified fragment of growth hormone designed to isolate its fat-burning properties. Animal studies showed promising results: oral dosing reduced weight gain by 50% in obese rats without affecting insulin sensitivity [10].

However, a 24-week Phase IIb human trial involving 536 subjects failed to show significant weight loss, and development was discontinued [11]. It remains a research compound without regulatory approval. Given that FDA-approved options like semaglutide and tirzepatide exist with strong efficacy data, AOD-9604 is hard to recommend as a primary fat-loss option.

CJC-1295 + Ipamorelin

The CJC-1295 and ipamorelin combination stimulates growth hormone release through two complementary pathways. A 2006 study showed CJC-1295 increased GH concentrations by 2- to 10-fold and IGF-1 by 1.5- to 3-fold in healthy adults aged 21-61 [12]. Ipamorelin was shown to be the first truly selective GH secretagogue, stimulating GH without raising cortisol or ACTH [13].

For women over 40, this combination can support improved body composition (less fat, more lean mass), better sleep quality, faster recovery, and improved skin health. However, one study evaluating long-term GHRH analog use in age-advanced adults found that anabolic benefits like lean body mass increases were more pronounced in men than women [14]. Women did see increased skin thickness, but the body composition improvements were less dramatic.

This doesn't mean the combination is ineffective for women -- it means expectations should be calibrated accordingly, and the protocol may need to be optimized differently than in men. Learn more about combining peptides in our Peptide Stacking Guide.

Sermorelin

Sermorelin is a GHRH analog with a shorter half-life than CJC-1295, making it a gentler option for growth hormone stimulation. It's sometimes preferred as a starting point for women new to peptide therapy.

Sermorelin works by stimulating the pituitary to produce GH in alignment with your body's natural circadian rhythm. Because the largest natural GH pulse occurs during deep sleep, sermorelin is typically administered at bedtime. Women often report improvements in sleep quality, which itself has cascading benefits for mood, recovery, and body composition.

Best Peptides for Skin, Collagen, and Anti-Aging

The collagen loss that accelerates during menopause is one of the most visible signs of hormonal change. These peptides specifically target skin health and cellular aging.

GHK-Cu

GHK-Cu is a naturally occurring copper-binding peptide found in human blood that declines with age. It's arguably the most well-studied peptide for skin health, with evidence spanning gene expression, collagen production, and clinical outcomes.

Research using the Broad Institute's Connectivity Map found that GHK modulates over 4,000 human genes, including those involved in collagen synthesis, DNA repair, and anti-inflammatory response [15]. At the cellular level, GHK-Cu increased both collagen and elastin production in human dermal fibroblasts while regulating the MMP/TIMP balance that controls tissue remodeling [16].

A clinical study comparing GHK-Cu creams to other topical treatments found collagen production increased in 70% of women treated with GHK-Cu, compared to 50% with vitamin C and 40% with retinoic acid [17].

For women over 40, this is particularly relevant. When menopause triggers a 30% collagen loss in five years [1], anything that stimulates new collagen production from the inside out -- rather than just preventing further loss -- has real value. GHK-Cu is available in topical, injectable, and oral forms, though topical absorption is limited by its high hydrophilicity [18].

Epitalon

Epitalon targets one of the most fundamental mechanisms of cellular aging: telomere shortening. This tetrapeptide activates telomerase, the enzyme responsible for maintaining telomere length. Khavinson et al. demonstrated that epitalon induced telomerase activity and telomere elongation in human somatic cells, with treated fibroblasts continuing to divide past the 44th passage while untreated controls stopped at 34 [19].

Beyond telomeres, epitalon influences melatonin production from the pineal gland [20]. Since melatonin naturally declines with age and plays a role in sleep regulation, circadian rhythm, and antioxidant defense, this secondary mechanism is relevant for women experiencing the sleep disruption common after 40.

A 2025 study in Biogerontology confirmed dose-dependent telomere extension in normal human cells, further supporting epitalon's anti-aging potential at the cellular level [21]. However, most evidence remains preclinical, and the peptide has no regulatory approval.

Collagen Peptides (Oral Supplementation)

While not the same category as the bioactive signaling peptides discussed elsewhere in this guide, oral collagen peptides deserve mention because they have some of the most accessible evidence for women over 40. Multiple randomized controlled trials have shown that oral collagen supplementation can improve skin elasticity, hydration, and wrinkle depth.

These work through a different mechanism than GHK-Cu: when you ingest collagen peptides, the digested fragments act as signaling molecules that stimulate fibroblasts to produce new collagen. They're not a replacement for peptides like GHK-Cu but can complement them as part of a broader approach.

Best Peptides for Recovery, Joints, and Inflammation

Joint pain, slower recovery, and persistent inflammation become increasingly common after 40. Estrogen has anti-inflammatory and tissue-protective properties, so its decline leaves joints and connective tissue more vulnerable.

BPC-157

BPC-157 is a 15-amino acid peptide derived from a protein in human gastric juice. Its preclinical track record for tissue healing is extensive: a 2024 systematic review of 36 studies spanning 1993 to 2024 confirmed consistent positive healing effects across tendon, ligament, muscle, and bone injury models [22].

Specific mechanisms include promoting angiogenesis (new blood vessel formation), upregulating growth hormone receptor expression in tendon fibroblasts [23], activating the FAK-paxillin cell migration pathway [24], and modulating nitric oxide pathways. BPC-157 also shows gastroprotective effects -- relevant for women over 40 who may be dealing with digestive issues that worsen during perimenopause.

Perhaps most interesting for this age group: BPC-157 has neuroprotective properties that may support cognitive health and help address the brain fog many women experience during hormonal transitions.

The major limitation remains: nearly all BPC-157 research is in animal models. Human clinical trials for musculoskeletal and gut applications are still needed. No adverse effects have been reported in preclinical studies, but the absence of human safety data means caution is warranted.

For more, see our guide on Best Peptides for Joint Health.

TB-500

TB-500 is a synthetic version of thymosin beta-4, a naturally occurring protein involved in tissue repair and cell migration. It works through actin regulation -- actin being a structural protein that cells need to move and organize. Where BPC-157 promotes healing through growth factor pathways and blood vessel formation, TB-500 supports the actual cellular movement and differentiation needed for tissue repair.

For women over 40 with chronic joint issues, tendon problems, or slow injury recovery, TB-500 is often paired with BPC-157 for a complementary approach. See our Peptide Stacking Guide for details on combining these peptides.

One safety concern: thymosin beta-4 has been found overexpressed in several cancer types. While administering TB-500 externally differs from endogenous overexpression, women with personal or family history of cancer should discuss this with their physician.

Thymosin Alpha-1

Thymosin Alpha-1 is a thymic peptide that modulates immune function rather than directly repairing tissue. During menopause, the immune system shifts toward increased inflammation -- a state sometimes called "inflammaging." TA-1 helps recalibrate this balance by supporting T-cell function and modulating inflammatory cytokines.

For women over 40 dealing with increased susceptibility to infections, autoimmune flares, or chronic low-grade inflammation that worsens around perimenopause, TA-1 addresses the immune dysregulation at its source. It's approved in over 30 countries for conditions including hepatitis B and C and as an immune adjuvant, though not in the United States.

Best Peptides for Energy, Sleep, and Cognitive Function

The triad of fatigue, poor sleep, and brain fog is perhaps the most disruptive set of symptoms women face after 40. These peptides target the underlying biology.

MOTS-c

MOTS-c is a mitochondrial-derived peptide that functions as an exercise mimetic. A 2021 study in Nature Communications showed that MOTS-c treatment allowed old mice to double their running time on a treadmill -- effectively outperforming their middle-aged counterparts [25]. In humans, exercise increased MOTS-c levels 11.9-fold in skeletal muscle.

This matters for women over 40 because mitochondrial function declines with age, and estrogen loss accelerates that decline. Estrogen normally supports mitochondrial efficiency in multiple tissues; without it, cellular energy production falters, contributing to fatigue, brain fog, and metabolic sluggishness.

MOTS-c works through the AMPK pathway to improve insulin sensitivity, support muscle homeostasis, and regulate metabolism. Plasma MOTS-c levels decline with age in both sexes [25]. Research has also linked MOTS-c to beneficial effects on postmenopausal obesity specifically [26].

SS-31 (Elamipretide)

SS-31 targets the inner mitochondrial membrane, specifically binding to cardiolipin -- a phospholipid essential for electron transport chain function. When mitochondria aren't working efficiently, cells produce less ATP (energy) and more reactive oxygen species (damage).

For women in perimenopause, declining estrogen weakens mitochondrial performance, particularly in energy-demanding tissues like the brain, heart, and skeletal muscle. SS-31 addresses this directly by stabilizing mitochondrial structure and improving energy output at the cellular level.

SS-31 has been in clinical trials for several conditions involving mitochondrial dysfunction. While not yet approved, it represents one of the more targeted approaches to the fatigue and cognitive decline that many women experience during hormonal transitions.

DSIP (Delta Sleep-Inducing Peptide)

DSIP is a neuropeptide that influences sleep architecture. It was originally isolated from rabbit brain during induced sleep and has been studied for its ability to promote slow-wave (deep) sleep -- the sleep phase most important for physical recovery, growth hormone release, and memory consolidation.

Sleep disruption is one of the earliest and most persistent symptoms of perimenopause. Hot flashes wake you up. Declining progesterone (a natural sedative) makes it harder to fall asleep. Cortisol dysregulation means your stress hormones may spike at 3 AM instead of staying quiet. DSIP may help restore more normal sleep patterns, though human clinical evidence remains limited.

For a deeper look at sleep-specific peptides, see Best Peptides for Sleep.

Selank

Selank is a synthetic peptide based on the naturally occurring immunomodulatory peptide tuftsin. It has anxiolytic (anti-anxiety) and nootropic (cognitive-enhancing) properties. Research shows it modulates GABA, serotonin, and dopamine systems without the sedation or dependence risk associated with benzodiazepines.

For women over 40 dealing with the anxiety, mood instability, and cognitive changes common during perimenopause, selank offers an interesting option. It's approved in Russia as an anti-anxiety medication but has no FDA approval in the United States. For more on cognitive-focused peptides, see Best Peptides for Cognitive Enhancement.

Best Peptides for Bone Health

Bone density loss accelerates dramatically after menopause, with women losing up to 20% of bone density in the first 5-7 years [4]. While estrogen replacement is the most direct approach, certain peptides may offer complementary support.

Ipamorelin (for Bone)

Beyond its growth hormone effects, ipamorelin has specific bone-building evidence. A study on adult rats showed that ipamorelin increased periosteal bone formation rate fourfold, even counteracting the bone-destroying effects of glucocorticoid treatment [27]. Growth hormone and IGF-1 -- both elevated by ipamorelin -- are important regulators of bone remodeling.

For women over 40, supporting GH output may help slow bone density loss alongside other interventions. This peptide's selectivity (no cortisol elevation, no disruption of other pituitary hormones) makes it particularly appropriate for this population.

Humanin

Humanin is a mitochondrial-derived peptide with cytoprotective properties. Research has shown it protects against cellular stress and apoptosis across multiple tissue types. While bone-specific research is still emerging, humanin's role in supporting cell survival and reducing oxidative stress may contribute to maintaining bone-forming osteoblast function during the high-turnover period after menopause.

For more on this topic, see our guide on Best Peptides for Bone Healing.

Peptide Comparison Table

PeptidePrimary Use for Women 40+MechanismFDA Approved?AdministrationResearch Quality
SemaglutideFat loss, metabolic healthGLP-1 receptor agonistYesInjection/oralVery strong (Phase 3)
TirzepatideFat loss, insulin resistanceDual GIP/GLP-1 agonistYesInjectionVery strong (Phase 3)
TesamorelinVisceral fat reductionGHRH analogYes (HIV indication)InjectionVery strong (Phase 3)
CJC-1295 + IpamorelinBody composition, sleep, recoveryGH secretagoguesNoInjectionStrong (human trials)
SermorelinGH support, sleepGHRH analogYes (diagnostic)InjectionStrong (human trials)
GHK-CuSkin, collagen, anti-agingGene expression modulationNoTopical/injectionModerate-strong
EpitalonCellular aging, sleepTelomerase activationNoInjectionModerate (limited human)
BPC-157Joint repair, gut health, brain fogGrowth factor modulationNoInjection/oralStrong (animal); weak (human)
TB-500Tissue repairActin regulationNoInjectionModerate (animal)
Thymosin Alpha-1Immune modulationT-cell supportApproved (30+ countries)InjectionStrong (human trials)
MOTS-cEnergy, metabolismAMPK pathwayNoInjectionModerate (early human)
SS-31Mitochondrial function, fatigueCardiolipin bindingNo (in trials)InjectionModerate (human trials)
DSIPSleep qualitySleep architectureNoInjectionWeak-moderate
SelankAnxiety, cognitive functionGABA/serotonin modulationYes (Russia only)IntranasalModerate (human trials)
GonadorelinHormonal regulationSynthetic GnRHYes (diagnostic)InjectionStrong (long clinical history)
KisspeptinHPG axis supportGnRH stimulationNoInjectionStrong (human; less in women 40+)
AOD-9604Fat lossGH fragmentNoInjection/oralWeak (failed human trials)

Peptides vs. Hormone Replacement Therapy

This is the question every woman over 40 eventually faces. Let's be clear about what each approach does.

Hormone replacement therapy (HRT) supplies estrogen and progesterone (or estrogen alone for women without a uterus) directly. It is the most effective treatment for hot flashes, night sweats, vaginal dryness, and bone density loss. Modern data from the Women's Health Initiative follow-up studies show that for women who start HRT within 10 years of menopause onset, the benefits generally outweigh the risks [28].

Peptide therapy works through different pathways. Growth hormone peptides stimulate the pituitary. BPC-157 promotes tissue repair. GHK-Cu boosts collagen production. MOTS-c supports mitochondrial function. None of these directly replace estrogen or progesterone.

FactorPeptide TherapyHRT
Hot flash reliefIndirect at bestVery effective
Bone protectionSupportive (GH/IGF-1)Directly protective
Body compositionModerate benefitModerate benefit
Collagen/skinStrong (GHK-Cu, GH peptides)Strong (estrogen effect)
Sleep improvementModerate (DSIP, GH peptides)Moderate-strong
Brain fogEmerging evidenceGood evidence
CardiovascularVaries by peptideTiming-dependent benefit
Cancer considerationsIGF-1 concerns with GH peptidesBreast cancer considerations

These aren't mutually exclusive. Many women over 40 use HRT for core menopausal symptoms and add specific peptides for goals HRT doesn't fully address -- like tissue repair (BPC-157), deeper body composition changes (GH peptides or semaglutide), skin health (GHK-Cu), or mitochondrial support (MOTS-c, SS-31).

One important interaction to know: oral estrogen therapy can reduce IGF-1 production, potentially blunting the effects of GH-stimulating peptides. Transdermal estrogen does not have the same effect [3]. If you're using both HRT and GH peptides, discuss estrogen delivery method with your provider.

Safety Considerations for Women

Women's physiology creates some unique safety considerations with peptide therapy.

The IGF-1 and breast cancer question. Any peptide that raises growth hormone also raises IGF-1. Elevated IGF-1 has been associated with increased breast cancer risk in epidemiological studies. This doesn't mean GH peptides cause cancer -- the relationship is complex and confounded by many factors. But it does mean that women with personal or strong family history of breast cancer need to have an honest conversation with their oncologist before using tesamorelin, CJC-1295, ipamorelin, sermorelin, or MK-677.

TB-500 and cancer. Thymosin beta-4 has been found overexpressed in several cancer types. While externally administered TB-500 is different from endogenous overexpression, the concern is not trivial for women over 40, who face increasing baseline cancer risk with age.

Pregnancy considerations. Some peptides affect hormones that regulate fertility. Kisspeptin and gonadorelin directly influence reproductive hormones. GH peptides indirectly affect fertility through IGF-1. If pregnancy is possible, inform your physician before starting any peptide protocol.

Drug interactions with HRT. As mentioned, oral estrogen blunts IGF-1 response. This isn't dangerous, but it can reduce the effectiveness of GH peptides. Transdermal estrogen delivery avoids this issue.

Baseline testing. Before starting peptide therapy, get thorough bloodwork: complete metabolic panel, thyroid function (TSH, free T3, free T4), sex hormones (estradiol, progesterone, testosterone, DHEA-S), IGF-1, CBC, inflammatory markers (CRP, ESR), and bone density (DEXA scan if not done recently). This baseline lets your physician track response and adjust protocols.

Monitoring. Recheck labs every 6-12 weeks initially, then every 3-6 months once stable. Watch IGF-1 levels in particular -- the goal is to reach upper-normal range, not exceed it.

Frequently Asked Questions

What's the best single peptide for women over 40? There's no universal answer because it depends entirely on your primary concern. For weight management with the strongest evidence, semaglutide or tirzepatide. For skin and collagen, GHK-Cu. For joint pain and recovery, BPC-157. For overall body composition, the CJC-1295 + ipamorelin combination. Start with your most pressing issue and build from there.

Should I try peptides before HRT, or alongside it? Most physicians would say HRT comes first for core menopausal symptoms (hot flashes, night sweats, vaginal dryness, bone protection). Peptides can complement HRT for goals it doesn't fully address -- fat loss, tissue repair, skin health, cognitive function. They work through different mechanisms, so combining them makes physiologic sense. The exception: if you can't or choose not to use HRT, certain peptides may partially address some of the same issues through alternate pathways.

How long do peptides take to work for women over 40? It depends on the peptide and the goal. Sleep improvements from GH peptides: 1-2 weeks. Body composition changes: 2-3 months. Skin improvements from GHK-Cu: 4-8 weeks topically, potentially faster with injection. Fat loss from semaglutide: measurable within weeks. Tissue repair from BPC-157: varies by injury but typically 4-8 weeks.

Are there peptides that help with hot flashes? Not directly. Hot flashes are driven by estrogen withdrawal affecting the hypothalamic thermoregulatory center. No peptide currently available reliably treats hot flashes the way estrogen or the newer NK3 receptor antagonists (like fezolinetant) do. Improving sleep quality with GH peptides or DSIP can reduce the downstream impact of hot flashes, but doesn't stop them.

Can peptides help with perimenopause brain fog? Several peptides show potential. BPC-157 has neuroprotective properties in preclinical models. Selank has been studied for cognitive enhancement and anxiety reduction. MOTS-c and SS-31 support mitochondrial function in brain cells, which estrogen loss impairs. None of these have been specifically tested for perimenopausal brain fog in clinical trials, but the biological rationale is sound.

What about peptides for hair loss during menopause? GHK-Cu has some evidence for hair follicle support, and GH peptides may help indirectly through IGF-1 (which plays a role in hair growth cycling). But hormonal hair loss during menopause is primarily driven by the estrogen/androgen ratio shift, and peptides don't directly address that mechanism. HRT and anti-androgen therapies remain more targeted for this complaint.

Are peptides safe during perimenopause? FDA-approved peptides (semaglutide, tirzepatide) have well-characterized safety profiles. Research peptides (BPC-157, MOTS-c, epitalon, etc.) generally show good preclinical safety but lack long-term human data. The hormonal complexity of perimenopause -- with already erratic hormone levels -- means that any intervention affecting the endocrine system should be carefully monitored. Always work with a physician experienced in both menopause management and peptide therapy.

For more women-specific peptide guidance, see our guides on Best Peptides for Hormonal Balance in Women and Best Peptides for Women Over 40.

The Bottom Line

Peptide therapy for women over 40 is a tool, not a cure-all. It works best as one part of a larger strategy that includes hormonal management, nutrition, strength training, sleep optimization, and stress reduction.

The strongest evidence belongs to the FDA-approved options: semaglutide and tirzepatide for weight management, tesamorelin for visceral fat. GHK-Cu has solid evidence for collagen and skin health. CJC-1295 + ipamorelin have strong human data for GH stimulation, though the body composition benefits appear more modest in women than men. BPC-157 has consistent preclinical evidence for tissue repair and gut health. Thymosin Alpha-1 has international clinical use for immune modulation.

The emerging frontier includes mitochondrial peptides like MOTS-c and SS-31, which address the cellular energy crisis that estrogen loss accelerates. These may prove particularly important for women, but human data is still early.

What won't work: expecting peptides to replace estrogen. Nothing replaces estrogen except estrogen. If your primary symptoms are hot flashes, night sweats, vaginal atrophy, and bone density loss, hormone replacement therapy remains the most evidence-based treatment.

What can work: using peptides to address the aspects of aging after 40 that exist alongside and beyond hormonal decline -- tissue repair, body composition, skin health, mitochondrial function, immune regulation, and cellular aging. When chosen carefully, monitored properly, and combined with solid lifestyle habits, they add a meaningful layer to the toolkit available to women navigating the second half of life.

References

  1. Brincat M, Versi E, Moniz CF, et al. Skin collagen changes in postmenopausal women receiving different regimens of estrogen therapy. Obstet Gynecol. 1987;70(1):123-127. PubMed

  2. Rzepecki AK, et al. Estrogens and aging skin. Dermatol Surg. 2019. Referenced in PMC review: PMC

  3. Leung KC, Johannsson G, Leong GM, Ho KK. Estrogen regulation of growth hormone action. Endocr Rev. 2004;25(5):693-721.

  4. North American Menopause Society. Management of osteoporosis in postmenopausal women: the 2021 position statement. Menopause. 2021.

  5. Gonadorelin prescribing information. DrugBank

  6. Topaloglu AK, et al. Inactivating KISS1 mutation and hypogonadotropic hypogonadism. N Engl J Med. 2012;366(7):629-635.

  7. Wilding JPH, Batterham RL, Calanna S, et al. Once-weekly semaglutide in adults with overweight or obesity. N Engl J Med. 2021;384(11):989-1002. PubMed

  8. Lincoff AM, et al. Long-term weight loss effects of semaglutide in obesity without diabetes in the SELECT trial. Nat Med. 2024;30:2049-2057. PubMed

  9. Falutz J, et al. Effects of tesamorelin (TH9507), a growth hormone-releasing factor analog, in HIV-infected patients with excess abdominal fat: a pooled analysis of two multicenter, double-blind placebo-controlled phase 3 trials. J Clin Endocrinol Metab. 2010;95(9):4291-4304. PubMed

  10. Ng FM, et al. Metabolic studies of a synthetic lipolytic domain (AOD9604) of human growth hormone. Horm Res. 2000;53(6):274-278. PubMed

  11. Heffernan MA, et al. The effects of human GH and its lipolytic fragment (AOD9604) on lipid metabolism. Endocrinology. 2001;142(12):5182-5189. PubMed

  12. Teichman SL, et al. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295 in healthy adults. J Clin Endocrinol Metab. 2006;91(3):799-805. PubMed

  13. Raun K, et al. Ipamorelin, the first selective growth hormone secretagogue. Eur J Endocrinol. 1998;139(5):552-561. PubMed

  14. Vittone J, et al. Endocrine and metabolic effects of long-term administration of [Nle27]GHRH-(1-29)-NH2 in age-advanced men and women. J Clin Endocrinol Metab. 1997;82(5):1472-1479. PubMed

  15. Pickart L, Margolina A. Regenerative and protective actions of the GHK-Cu peptide in the light of the new gene data. Int J Mol Sci. 2018;19(7):1987. PMC

  16. Badenhorst T, et al. Effects of GHK-Cu on MMP and TIMP expression, collagen and elastin production and facial wrinkle parameters. J Aging Sci. 2016;4(1):166.

  17. Leyden JJ, et al. Clinical study of GHK-Cu effects on facial skin. Cited in Pickart L, Margolina A. Int J Mol Sci. 2018.

  18. Recent tripeptide review. Limitations of GHK-Cu: short in vivo half-life, high hydrophilicity limiting skin absorption. Int J Med Sci. 2025. Link

  19. Khavinson VKh, Bondarev IE, Butyugov AA. Epithalon peptide induces telomerase activity and telomere elongation in human somatic cells. Bull Exp Biol Med. 2003;135(6):590-592. PubMed

  20. Khavinson VK. Peptides and ageing. Neuroendocrinol Lett. 2002;23(Suppl 3):11-144.

  21. Epitalon increases telomere length in human cell lines through telomerase upregulation or ALT activity. Biogerontology. 2025. PMC

  22. Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review. Cureus. 2024. PMC

  23. Gwyer D, et al. Pentadecapeptide BPC 157 enhances the growth hormone receptor expression in tendon fibroblasts. Molecules. 2018;23(7):1313. PMC

  24. Chang CH, et al. The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration. J Appl Physiol. 2011;110(3):774-780. PubMed

  25. Reynolds JC, et al. MOTS-c is an exercise-induced mitochondrial-encoded regulator of age-dependent physical decline and muscle homeostasis. Nat Commun. 2021;12(1):470. PubMed

  26. Mitochondria-derived peptide MOTS-c: effects and mechanisms related to stress, metabolism and aging. J Transl Med. 2023. PMC

  27. Svensson J, et al. The growth hormone secretagogue ipamorelin counteracts glucocorticoid-induced decrease in bone formation of adult rats. Growth Horm IGF Res. 2001;11(6):404-411. PubMed

  28. Manson JE, et al. Menopausal hormone therapy and long-term all-cause and cause-specific mortality: the Women's Health Initiative randomized trials. JAMA. 2017;318(10):927-938.